BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2562178)

  • 1. Forward and reverse changes in Ig/myc translocation carrying tumors.
    Klein G
    Princess Takamatsu Symp; 1989; 20():135-42. PubMed ID: 2562178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological aspects of B-cell derived tumors in humans and rodents.
    Klein G
    Princess Takamatsu Symp; 1988; 19():3-13. PubMed ID: 2855874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EBV-B cell interactions: immortalization, rescue from apoptosis, tumorigenicity (a short review).
    Klein G
    Acta Microbiol Immunol Hung; 1996; 43(2-3):97-105. PubMed ID: 8876725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversion of tumorigenicity in an EBV-converted Burkitt's lymphoma line.
    Klein G
    Ciba Found Symp; 1989; 142():36-48; discussion 48-53. PubMed ID: 2545422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors.
    Klein G
    AIDS Res; 1986 Dec; 2 Suppl 1():S167-76. PubMed ID: 3030345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-MYC impairs immunogenicity of human B cells.
    Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
    Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
    Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
    Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
    Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
    EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus and Burkitt's lymphoma.
    Magrath I; Jain V; Bhatia K
    Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53.
    Ramqvist T; Magnusson KP; Wang Y; Szekely L; Klein G; Wiman KG
    Oncogene; 1993 Jun; 8(6):1495-500. PubMed ID: 8502475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
    Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
    Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conditioned tumorigenicity of activated oncogenes.
    Klein G; Klein E
    Cancer Res; 1986 Jul; 46(7):3211-24. PubMed ID: 3011242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stable nontumorigenic phenotype of somatic cell hybrids between malignant Burkitt's lymphoma cells and autologous EBV-immortalized B cells despite induction of chromosomal breakage and loss.
    Jox A; Taquia E; Vockerodt M; Draube A; Pawlita M; Möller P; Bullerdiek J; Diehl V; Wolf J
    Cancer Res; 1998 Nov; 58(21):4930-9. PubMed ID: 9810002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
    Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
    Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiimmunoglobulin inhibition of Burkitt's lymphoma cell proliferation and concurrent reduction of c-myc and mu heavy chain gene expression.
    Arasi VE; Lieberman R; Sandlund J; Kiwanuka J; Novikovs L; Kirsch I; Hollis G; Magrath IT
    Cancer Res; 1989 Jun; 49(12):3235-41. PubMed ID: 2497974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
    Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
    Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosomal translocations in B-cell derived tumors.
    Klein G
    Princess Takamatsu Symp; 1986; 17():159-70. PubMed ID: 3332008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell phenotype dependent expression of MHC class I antigens in Burkitt's lymphoma cell lines.
    Masucci MG; Klein E
    Semin Cancer Biol; 1991 Feb; 2(1):63-71. PubMed ID: 1655115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
    Kelly G; Bell A; Rickinson A
    Nat Med; 2002 Oct; 8(10):1098-104. PubMed ID: 12219084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potential role for antigen selection in the clonal evolution of Burkitt's lymphoma.
    Jain R; Roncella S; Hashimoto S; Carbone A; Francia di Celle P; Foa R; Ferrarini M; Chiorazzi N
    J Immunol; 1994 Jul; 153(1):45-52. PubMed ID: 8207254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.